These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 15555218

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
    Saad F, Chen YM, Gleason DM, Chin J.
    Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S.
    J Clin Oncol; 2005 May 20; 23(15):3314-21. PubMed ID: 15738536
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.
    Clin Breast Cancer; 2012 Aug 20; 12(4):247-58. PubMed ID: 22694824
    [Abstract] [Full Text] [Related]

  • 11. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ, Kaura S.
    J Med Econ; 2012 Aug 20; 15(1):175-84. PubMed ID: 22017235
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
    Rosen LS, Gordon DH, Dugan W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE.
    Cancer; 2004 Jan 01; 100(1):36-43. PubMed ID: 14692022
    [Abstract] [Full Text] [Related]

  • 13. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G.
    Oncology; 2004 Sep 15; 67(5-6):390-6. PubMed ID: 15713995
    [Abstract] [Full Text] [Related]

  • 17. Optimal management of metastatic bone disease.
    Major P.
    Eur J Oncol Nurs; 2007 Sep 15; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.